Last reviewed · How we verify
SP01A
At a glance
| Generic name | SP01A |
|---|---|
| Sponsor | Samaritan Pharmaceuticals, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients (PHASE2)
- A Dose Response and Safety Study of Procaine HCl in HIV-Infected Patients (PHASE1, PHASE2)
- A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SP01A CI brief — competitive landscape report
- SP01A updates RSS · CI watch RSS
- Samaritan Pharmaceuticals, Inc portfolio CI